Successful Use of Fosmanogepix for Treatment of Rare Highly Resistant Cutaneous Fusariosis in a Pediatric Patient With STAT3 Hyper-Immunoglobulin E Syndrome and End-Stage Kidney Disease

• Type of Material: Article
• Authors: Kathryn P. Goggin, Emory University; Jackson Londeree, Emory University; Alexandra F. Freeman, National Institute of Allergy and Infectious Diseases; Rouba Garro, Emory University; Roshan George, Emory University
• Language: English
• Date: 2023-06-01
• Publisher: Oxford University Press
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1093/ofid/ofad285
• Title of Journal or Parent Work: Open Forum Infectious Diseases
• Volume: 10
• Issue: 6
• Start Page: ofad285
• End Page: ofad285
• Grant/Funding Information: We received no financial support for the research and authorship of this article. The publication of this article was supported in part by Emory University's Open Access Publishing Fund . This work was supported in part by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
• Research Categories: Health Sciences, Immunology; Health Sciences, Pharmacology

Abstract

We describe the successful use of the novel antifungal drug fosmanogepix to treat a chronic case of multidrug-resistant cutaneous Fusarium suttonianum infection in a pediatric patient with STAT3 hyper-IgE syndrome and end-stage kidney disease on peritoneal dialysis.